Targeting CD38 to suppress osteoarthritis development and associated pain after joint injury in mice.
Paulo Gil AlabarseLiang-Yu ChenPatricia OliveiraHuaping QinRu Liu-BryanPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
CD38 deficiency exerts OA disease modifying effects. Inhibition of CD38 has a potential to be a novel therapeutic approach for OA treatment.